• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiology and Oncology >Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
【24h】

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience

机译：贝伐单抗和伊立替康治疗复发性恶性神经胶质瘤的单一机构经验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. Patients and methods. The medical documentation of 19 adult patients with recurrent malignant gliomas was retrospectively reviewed. All patients received bevacizumab (10 mg/kg) and irinotecan (340 mg/m2 or 125 mg/m2) every two weeks. Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated. Results. Between August 2008 and November 2011, 19 patients with recurrent malignant gliomas (median age 44.7, male 73.7%, WHO performance status 0-2) were treated with bevacizumab/irinotecan regimen. Thirteen patients had glioblastoma, 5 anaplastic astrocytoma and 1 anaplastic oligoastrocytoma. With exception of one patient, all patients had initially a standard therapy with primary resection followed by postoperative chemoradiotherapy. Radiological response was confirmed after 3 months in 9 patients (1 complete response, 8 partial responses), seven patients had stable disease and three patients have progressed. The median PFS was 6.8 months (95% confidence interval [CI]: 5.3-8.3) with six-month PFS rate 52.6%. The median OS was 7.7 months (95% CI: 6.6-8.7), while six-month and twelve-month survival rates were 68.4% and 31.6%, respectively. There were 16 cases of hematopoietic toxicity grade (G) 1-2. Non-hematopoietic toxicity was present in 14 cases, all G1-2, except for one patient with proteinuria G3. No grade 4 toxicities, no thromboembolic event and no intracranial hemorrhage were observed. Conclusions. In recurrent malignant gliomas combination of bevacizumab and irinotecan might be an active regimen with acceptable toxicity.
机译：背景。复发性恶性神经胶质瘤的治疗选择非常有限，并且生存获益较差。 II期试验的结果表明，贝伐单抗和伊立替康的组合是有益的。患者和方法。回顾性分析了19例成人恶性神经胶质瘤复发患者的医学文献。所有患者每两周接受贝伐单抗（10 mg / kg）和伊立替康（340 mg / m2或125 mg / m2）。评估患者的临床特征，药物毒性，缓解率，无进展生存期（PFS）和总生存期（OS）。结果。在2008年8月至2011年11月之间，接受了贝伐单抗/伊立替康治疗的19例复发性恶性神经胶质瘤患者（中位年龄44.7，男性73.7％，WHO工作状态为0-2）。胶质母细胞瘤13例，间变性星形细胞瘤5例，间变性星形细胞瘤1例。除一名患者外，所有患者最初均接受标准疗法，即初次切除，然后进行术后放化疗。 3个月后确诊9例患者的放射学反应（1例完全缓解，8例部分缓解），7例病情稳定，3例进展。 PFS中位数为6.8个月（95％置信区间[CI]：5.3-8.3），六个月PFS率为52.6％。中位OS为7.7个月（95％CI：6.6-8.7），而六个月和十二个月生存率分别为68.4％和31.6％。造血毒性（G）1-2级16例。除一名G3蛋白尿患者外，其余14名患者均存在非造血系统毒性，均为G1-2。没有观察到4级毒性，没有发生血栓栓塞事件，也没有观察到颅内出血。结论。在复发性恶性神经胶质瘤中，贝伐单抗和伊立替康的联合治疗可能是一种有效的方案，具有可接受的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号